EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study

Juthapa Pongklaokam iD, Woraphong Manuskiatti iD, Rungsima Wanitphakdeedecha iD, Pitchaya Maneeprasopchoke, Panwadee Thongjaroensirikul, Yanin Nokdhes, Rona Maria R Abad-Constantino, Woramate Bhorntarakcharoen iD, Sariya Sittiwanaruk, Thanya Techapichetvanich iD

Toxins · 2025

DOI: 10.3390/toxins17070349 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Toxins, 2025. Verfasst von Juthapa Pongklaokam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand. Hauptthemen laut MEDLINE: Melanosis, Botulinum Toxins, Type A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hugel Inc., located at 61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do, 24203, Republic of Korea., Hugel Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits.

Objective

We sought to evaluate the efficacy and safety of two intradermal dilutions of Letibotulinum toxin A (LetiBoNT-A) in Thai patients with melasma.

Methods

In this randomized, double-blind, split-face study, 30 participants aged 32–62 years received a single intradermal injection of LetiBoNT-A, with 20 units administered per cheek. A 1:5 dilution was injected on one side of the face, and a 1:10 dilution was injected on the contralateral side. Outcomes were evaluated over a 6-month period using the Hemi-modified Melasma Area and Severity Index (Hemi-mMASI), VISIA® brown spot analysis, and quantitative assessments of skin texture.

Results

Both dilutions significantly improved Hemi-mMASI scores (1:5, p = 0.043; 1:10, p = 0.002) and brown spots (1:5, p = 0.002; 1:10, p < 0.001). The 1:10 dilution showed earlier and more sustained improvements. Subgroup analysis revealed greater reductions in Hemi-mMASI scores among patients with telangiectatic melasma, particularly with the 1:10 dilution, though they were not statistically significant. Additionally, the 1:10 dilution significantly reduced pore volume, pore area, and sebum levels. One case of transient facial asymmetry was reported with the 1:5 dilution.

Conclusions

LetiBoNT-A is a safe and effective adjunct in melasma treatment. The 1:10 dilution offered superior clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanosisBotulinum Toxins, Type AHumansAdultDouble-Blind MethodFemaleMiddle AgedMaleTreatment OutcomeInjections, Intradermal

Stichwörter der Autor:innen

Letibotulinum toxin Ahyperpigmentationmelasma

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand.
  • Department of Dermatology, Research Institute for Tropical Medicine, 9002 Research, Mutinlupa 1781, Philippines.

ORCID-Profile: Juthapa Pongklaokam, Woraphong Manuskiatti, Rungsima Wanitphakdeedecha, Woramate Bhorntarakcharoen, Thanya Techapichetvanich

Förderung

  • Hugel Inc., located at 61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon-si, Gangwon-do, 24203, Republic of Korea.
  • Hugel Inc.

Zitieren

APA

Pongklaokam, J., Manuskiatti, W., Wanitphakdeedecha, R., Maneeprasopchoke, P., Thongjaroensirikul, P., Nokdhes, Y., Abad-Constantino, R. M. R., Bhorntarakcharoen, W., Sittiwanaruk, S., & Techapichetvanich, T. (2025). Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study. Toxins. https://doi.org/10.3390/toxins17070349

Vancouver

Pongklaokam J, Manuskiatti W, Wanitphakdeedecha R, Maneeprasopchoke P, Thongjaroensirikul P, Nokdhes Y, et al. Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study. Toxins. 2025. doi:10.3390/toxins17070349

BibTeX
@article{Pongklaokam2025,
  author = {Pongklaokam, Juthapa and Manuskiatti, Woraphong and Wanitphakdeedecha, Rungsima and Maneeprasopchoke, Pitchaya and Thongjaroensirikul, Panwadee and Nokdhes, Yanin and Abad-Constantino, Rona Maria R and Bhorntarakcharoen, Woramate and Sittiwanaruk, Sariya and Techapichetvanich, Thanya},
  title = {Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Melasma in Two Different Dilutions: A Randomized Double-Blind Split-Face Study},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17070349}
}
Kostenlos starten →